Alzamend Neuro Files 8-K on Operations

Ticker: ALZN · Form: 8-K · Filed: Jul 23, 2025 · CIK: 1677077

Alzamend Neuro, INC. 8-K Filing Summary
FieldDetail
CompanyAlzamend Neuro, INC. (ALZN)
Form Type8-K
Filed DateJul 23, 2025
Risk Levellow
Sentimentneutral

Sentiment: neutral

Topics: financial-condition, operations, disclosure

TL;DR

Alzamend Neuro dropped an 8-K detailing financials - check it out!

AI Summary

Alzamend Neuro, Inc. filed an 8-K on July 23, 2025, reporting on its results of operations and financial condition. The filing includes financial statements and exhibits, with the company's principal executive offices located at 3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326. The company is incorporated in Delaware and operates in the Pharmaceutical Preparations industry.

Why It Matters

This 8-K filing provides an update on Alzamend Neuro's financial status and operational results, which is crucial for investors to assess the company's performance and future prospects.

Risk Assessment

Risk Level: low — This filing is a routine disclosure of operational and financial information, not indicating any immediate or significant new risks.

Key Players & Entities

FAQ

What specific financial information is being reported in this 8-K?

The 8-K indicates it covers 'Results of Operations and Financial Condition' and includes 'Financial Statements and Exhibits'.

When was this 8-K filing submitted?

The filing was submitted on July 23, 2025.

What is Alzamend Neuro, Inc.'s primary business sector?

Alzamend Neuro, Inc. is in the Pharmaceutical Preparations sector, with a Standard Industrial Classification code of 2834.

Where are Alzamend Neuro, Inc.'s principal executive offices located?

The principal executive offices are located at 3500 Lenox Rd. NE, Suite 1500, Atlanta, GA 30326.

In which U.S. state was Alzamend Neuro, Inc. incorporated?

Alzamend Neuro, Inc. was incorporated in Delaware.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on July 23, 2025 regarding Alzamend Neuro, Inc. (ALZN).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on Read The Filing